Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.

Service

Funding, debt advisory & ECM

Parties

“It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. Oaklins’ team has always been supportive and built a good register of institutions in March which was broadened further in this funding. It was a very successful fundraising and the level of demand was such that we were comfortably able to increase the size of the funding. Having demonstrated the great promise of SNG001 in hospitalized COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need.”

Richard Marsden

CEO, Synairgen plc

Talk to the deal team

Geoff Nash

Partner

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

Rotem Shani has completed an IPO

Real Estate

Rotem Shani has completed an IPO

Rotem Shani Ltd has completed an IPO to refinance and develop the company.

Learn more

Dutch Dental Group has raised new acquisition debt from ING Bank to support its growth strategy

Private Equity | Healthcare

Dutch Dental Group has raised new acquisition debt from ING Bank to support its growth strategy

Dutch Dental Group (DDG) has raised a new debt financing package provided by ING Bank, consisting of term loans, an acquisition facility and an RCF.

Learn more

Groupe Voie Lactée has been acquired by Initiative & Finance

Private Equity | Healthcare

Groupe Voie Lactée has been acquired by Initiative & Finance

JFC Industrie has sold Groupe Voie Lactée to Initiative & Finance.

Learn more